Monroe Carell Jr. Children's Hospital at Vanderbilt
Monroe Carell Jr. Children's Hospital at Vanderbilt
Monroe Carell Jr. Children's Hospital at Vanderbilt
Children's Hospital Logo
Connect With Us:

Monroe Carell Jr.
Children's Hospital
at Vanderbilt
2200 Children's Way
Nashville, TN 37232


(615) 936-1000

Children's Hospital Logo
Printer friendly version of this page  E-mail someone a link to this pageBookmark and Share

Experimental Therapeutics

 

Survival rates for children with cancer have dramatically improved over the last 40 years. More than 75 percent of children with cancer can now be cured with available treatments, including surgery, chemotherapy, radiation therapy and stem cell transplantation.

The Childhood Cancer Program at Children's Hospital is a national leader in clinical research studies for childhood cancer. Many of our clinical trials for newly diagnosed patients are conducted through the Children's Oncology Group (COG).

Currently, available treatments do not provide a cure for all childhood cancers. For children whose cancer has not responded to standard treatments, or whose cancer has recurred after standard treatments, the Childhood Cancer Program at Children's Hospital is a place of hope and healing. Our Experimental Therapeutics Program provides access to the latest new investigational treatments for recurrent or refractory leukemias, brain tumors, sarcomas and other childhood cancers through our participation in four highly specialized clinical research consortia.

SARC
The Vanderbilt Childhood Cancer program and the Vanderbilt-Ingram Cancer Center have joined the Sarcoma Alliance for Research Through Collaboration (SARC), a clinical trials organization conducting early phase trials for adults and children with sarcomas.

PBMTC
The Vanderbilt Childhood Cancer Program is a member of the Pediatric Blood and Marrow Transplant Consortium (PBMTC), a group of clinicians and scientists whose purpose is to engage in scientific and educational activities related to the use of hematopoietic stem cells in the treatment of diseases of children and adolescents.

TACL
The Vanderbilt Childhood Cancer program is a member of the Therapeutic Advances in Childhood Leukemia (TACL) consortium, a group of institutions that work closely together to rapidly develop and carry out early studies of new drugs in children with recurrent leukemias.

Find a Clinical Trial : Vanderbilt-Ingram Cancer Center

 


Last Edited: August 2, 2017
Valued Participant of Vanderbilt Health Affiliated Network